rss
Ann Rheum Dis 2008;67:1339-1342 doi:10.1136/ard.2008.090910
  • Concise report

Effect of intra-articular infliximab on synovial membrane pathology in a patient with a seronegative spondyloarthropathy

  1. M J Ahern,
  2. D G Campbell,
  3. H Weedon,
  4. V Papangelis,
  5. M D Smith
  1. Rheumatology Research Unit, Repatriation General Hospital, South Australia
  1. Professor M D Smith, Repatriation General, Hospital, Daws Rd, Daw Park, 5041 South Australia; Malcolm.smith{at}rgh.sa.gov.au
  • Accepted 7 April 2008
  • Published Online First 13 April 2008

Abstract

Objective: To demonstrate the efficacy of intra-articular infliximab in a patient with a persistent monarthritis who had previously had two arthroscopic synovectomies with limited success, and to determine the effect of intra-articular infliximab on synovial membrane pathology

Method: Arthroscopic synovial biopsy specimens were collected before and after treatment with intra-articular infliximab. The synovial tissue was stained for a range of inflammatory cell subsets, cell adhesion molecules and cytokines using immunohistochemical techniques and quantified using digital image analysis and a semiquantitative scoring method.

Results: Clinical improvement in the knee synovitis was seen after the first two intra-articular infliximab treatments, with a sustained clinical remission lasting for more than 12 months after the third treatment. Significant changes in cellular infiltration and expression of cytokines and cell adhesion molecules occurred as a result of treatment with intra-articular infliximab, with a reduction in some but not all cells in the inflammatory infiltrate, as well as a reduction in the expression of cell adhesion molecules (intercellular adhesion molecule-1 and vascular adhesion molecule-1) and production of cytokines (interleukin 1β and tumour necrosis factor α).

Conclusion: Intra-articular infliximab administration is a viable treatment for a persistent monarthritis resistant to other treatment options and can successfully modulate the inflammatory milieu within the synovial membrane.

Footnotes

  • Funding: Supported by the Daw Park Research Foundation, National Health and Medical Research Council of Australia and the Arthritis Foundation of Australia.

  • Competing interests: None declared.

  • Ethics approval: Ethics committee approval obtained.

  • Patient consent: Obtained.

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.